MODIFIED PROPOSAL FOR A COUNCIL DECISION ADOPTING A SPECIFIC RESEARCH AND TECHNOLOGICAL DEVELOPMENT PROGRAMME IN THE FIELD OF HEALTH: HUMAN GENOME ANALYSIS: ( 1990 - 1991 )
Date: 1989-11-13
Institutions: European Commission
Subjects: action programme, genetic engineering, public health, research and development, scientific progress

COMMISSION  OF  THE  EUROPEAN  COMMUNITIES 

COM (89) 532  final  -  SYN 146 

Brussels, 13  November 1989 

MODIFIED PROPOSAL FOR A COUNCIL DECISION 

Adopting a specific research and technological development programme 

in the field of health: 

Human Genome Analysis: (1990-19S1) 

(Presented by the Comrussion in accordance with 

Article 149, paragraph 3 of the EEC Treaty) 

* 

- 2 -

Explanatory Memorandum 

A. The  first  reading  of  the  "Proposal  for  a  Council  Decision  adopting  a 

specific research programme in the field of health: Predictive Medicine: 

Human Genome Analysis  (1989 - 1991)"(*) was carried out by the European 

Parliament during the part-session from 13 - 17 February 1989. 

The essential message of the 38 amendnents adopted by the Parliament is as 

follows: "The technical content of the research programme proposed by the 

Commission  is justified, but care must be  taken to see that individual 

rights  are  protected  and  respected  while  it  is  being  carried  out. 

Furthermore, it  is essential to guarantee that throughout the programme 

the ethical, social and legal problems which may arise out of applications 

of  ever  more  precise  knowledge  of  the  human  genome  are  examined  and 

debated. This debate  should also  identify  the  limits beyond which  such 

applications would become unacceptable by society". 

B. The expression "Predictive Medicine" is no longer used in the title of the 

programme. It has reverted to "Human Genome Analysis", which corresponds 

to  reality  since  the main  aim  is  to  increase  our  knowledge  of  human 

genetics. However, it is possible that this type of research, which will 

certainly lead to improvements in the treatment of patients suffering from 

certain  diseases  of  genetic  origin,  will  also  lead  subsequently  to 

applications in predictive medicine. But the social acceptability of such 

applications must first be carefully evaluated. 

The modified proposal is drafted in such a way as to guarantee the respect 

both of rules accepted by or acceptable to our democratic society and of 

the integrity and dignity of the person, not only while the programme is 

running but also in its medium- and long-term consequences. 

The clear affirmation of the respect for the integrity and dignity of the 

person  has  consequences  of which  several  aspects  are  defined  in  the 

modified proposal. The consequences both for the individual and for 

society of the application of the results obtained by research on the 

human genome must be analysed at the same time as the research is being 

(*) COM(88) 424 final, 20 July 1988 

- 3 -

carried  out.  Possible  abuses  must  be  identified,  as  must,  where 

appropriate, recommended national or Community  legislative measures. This 

task  will  be  carried  out  by  the  Commission  assisted  by  a  high-level 

committee which  it will  set up for this purpose, representing different 

areas  of  science,  law,  philosophy  and  ethics,  together  with 

representatives of patients* associations. 

The  term  "eugenics"  which  is  contained  in  amendment  no.  10  lacks 

precision. For this reason it is not used directly  in the proposal. The 

approach  described  above  guarantees  the exclusion  from the programme  of 

any  tendency  towards  a  type  of  eugenics  which  would  involve  the 

"selection"  of  the  human  species  by  genetic  means. This  guarantee  is 

further strengthened by the explicit exclusion of all research seeking to 

modify  human  genetic  heritage  by  the  alteration  of  germ  cells, in 

accordance with Parliament's request  (amendments nos. 21 and 33). But the 

modified proposal goes further: it excludes all intervention at any stage 

in the development of the embryo which might lead to hereditary changes. 

This technical possibility is indeed conceivable, and it must be rejected. 

Protection  is  guaranteed  of  the  confidentiality  of  information  gained 

during the research and of the anonymity of those concerned. 

The prenormative nature of the scientific data acquired, to be available 

to legislative authorities in particular, is highlighted. 

Lastly, progress reports on the research and on studies of ethical, social 

and  legal  problems will  be  submitted  annually  to  the  Council  and the 

European Parliament, and measures will be taken to keep the public fully 

informed of the Community action. 

C. As far as the European Parliament*s amendments are concerned: 

-  amendnents Nos. 1, 3, 4, 7, 11, 12, 16, 17, 21, 22, 23, 28, 32, 33, 35 

and 36 have been incorporated in the modified proposal. Amendnents 21 

and  33  have  been  supplemented to  clarify  the exclusion  of  all work 

seeking to "select" the human species. 

- 4 -

the intentions expressed in amendments nos. 5, 6, 8, 9, 10, 13, 20, 25, 

26 and 41 are incorporated in the modified proposal in different terms, 

sometimes regrouped or at places in the text other than those foreseen 

in the amendments. 

amendments  nos.  14,  15,  18, 19, 24, 27, 29, 30, 31, 34, 39  and 44 

(budgetary amendment) are  not  incorporated  in the proposal. However, 

the modified proposal expresses  the  ideas contained  in some of these 

amendments, especially nos. 14, 15, 18, 19, 27, 29, 30 and 39. 

- 5 -

MODIFIED PROPOSAL FOR A COUNCIL DECISION 

Adopting a specific research and technological development programme 

in the field of health: 

Human Genome Analysis: (1990-1991) 

(Presented by the Commission in accordance with 

Article 149, paragraph 3 of the EEC Treaty) 

THE COUNCIL OF THE EUROPEAN COMMUNITIES 

Having regard to the Treaty establishing the European Economic Community, and 

in particular to Article 130 Q (2) thereof, 

Having regard to the proposal from the Commission(*), 

In cooperation with the European Parliament(2), 

Having regard to the opinion of the Economic and Social Committee^), 

Whereas Article 130 K of the Treaty stipulates that the framework programme 

shall  be  implemented  through  specific  programmes  developed within  each 

activity; 

Whereas by  its Decision of 28 September  1987(4) the Council has adopted a 

framework  programme  of  Community  research  and  technological  development 

(1987-1991), in which  it  provided  for  activities to be undertaken  in the 

field of healthj 

h  OJ  H* 

2) OJ N° 

3) OJ N° C 56/47, 6.3.1989 

4) OJ N° L 302, 24.10.87, p. 1 

- 6 -

Whereas, for the evaluation of each specific programme and the selection of 

Community actions, the framework programme sets out criteria among which is 

that  of  contributing  to  the  strengthening  of  the  economic  and  social 

cohesion  of  the  Community,  consistent  with  the  pursuit  of  scientific  and 

technical quality; 

Whereas two successive pluriannual programmes of research and training of the 

European Economic Coniminity in the field of biotechnologies(5), of which the 

second is still in progress, have shown the possibility and usefulness of a 

Cormunity action promoting the utilization of modern biology for scientific 

and industrial purposes; 

Whoreas  the  framework  programme  has  foreseen  in  its  activity  "Quality of 

life" under the "Health" line 1.1, the initiation of new activities relating 

to the development of knowledge of the human genome; 

Whereas a specific programme to study the human genome is therefore necessary 

and, in particular, it is necessary to: 

develop  and spread the basic  technologies  concerning  the  study of the 

human genome, with  the  intention of  improving knowledge of matters of 

medical importance, 

improve  the  resolution  of  the  human  genetic  map  and  to  refine  the 

physical map by the creation of ordered clone libraries, as a basis for 

locating  genes  of  medical  importance  and  for  a  better  general 

understanding of gene function, and 

organise  networks  and  coordination, on  a  European  and  international 

scale, of researchers from all disciplines working in this field; 

Whereas  the  carrying  out  of  the  above-mentioned  goals  requires  the 

undertaking at Community level of actions aiming at: 

filling some existing gaps in scientific and technological knowledge, and 

encouraging  cooperation  between  European  research  institutions  with  a 

view  to  furthering  the  development  of  existing  technologies  while 

5) OJ N° L 375, 20.12.1981, p. 1; OJ N° L 83, 25.3.1985, p. 1 

- 7 -

promoting  all  research  sectors  capable  of  generating  new  lines  of 

research; 

Whereas,  simultaneously,  measures  will  be  taken  to  promote  cooperation 

between  the  Community  programme  and  similar  ones  developed  in  non-Member 

States or by international organizations; 

Whereas the right to a genetic identity forms part of the integrity and the 

dignity  of  an  individual,  and  this  principle  is  recognized  in  the 

constitutions and laws of Member States and in the Community legal system as 

forming part of the fundamental rights for which respect is ensured; 

Whereas the results which can be achieved from human genome research require 

the development of an integrated approach taking into account ethical, social 

and legal aspects of their possible applications  and the need to avoid any 

improper use of those results; 

Whereas there are good grounds for guaranteeing  the right of an individual 

in complete possession of the facts to choose whether or not to be informed 

of his genetic characteristics; 

Whereas, in the absence of clear standards and provisions concerning possible 

developments in the field of genome analysis, there may be a risk on the one 

hand that  attempts  are made  to  intervene  in the human genome  in order to 

make the modifications so obtained hereditary, and on  the other  hand that 

genetic  analyses  are carried out  for monitoring  purposes which may have a 

profound effect on social life; whereas there are, accordingly, good grounds 

for  taking  the  necessary  steps  to  preclude  unacceptable  developments, 

particularly as regards predictive medicine; 

Vfoereas, furthermore, it  is necessary to develop during the course of the 

programme  the prenormative  aspects  arising  from human  genome  analysis  by 

establishing a reliable scientific data set which could provide a basis for 

political authorities to establish sound,, clear and responsible regulations; 

Whereas the Scientific and Technical ResearchCommittee (CREST) was consulted 

on the following measures, 

HAS ADOPTED THIS DECISION: 

- 8 -

Article 1 

A specific research and technological development programme for the European 

Economic Community in the field of Human Genome Analysis, as defined in the 

Annex, is hereby adopted for a period of two years commencing on 1 January 

1990. 

Article 2 

The amount deemed necessary as the financial contribution from the Community 

for the execution of the programme  is 15 million ECU, including costs of a 

staff of two persons. 

Article 3 

Detailed rules for the implementation of the programme are set out  ia the*? 

Annex. 

Article 4 

1.  The Commission shall send to the Council and to the European Parliament 

an annual report on the progress of the programme. 

2.  In the second year of the programme implementation, the Commission shall 

undertake a review of the programme and it shall send the results of this 

review  to  the  Council  and  to  the  European  Parliament, together, if 

necessary, with  any proposals  for modification  or  prolongation  of  the 

programme. 

3.  An evaluation of the results achieved shall be carried out by independent 

experts and published in the form of a communication to the Council and 

to the European Parliament. 

4.  The  above-mentioned  reports  shall be established taking account of the 

objectives and evaluation criteria set out in the Annex to this decision 

and  in  conformity  with  the  provisions  of Article  2, paragraph  2 of 

Decision 87/516/Euratom, EEC. 

- 9 -

Article 5 

The Commission shall be responsible for the implementation of the programs. 

It shall be assisted in its execution by an advisory committee, hereinafter 

called  "the  committee", composed  of  representatives  of Member  States  and 

chaired by a representative of the Commission. 

Article 6 

1.  The Commission shall submit to the committee a draft of the measures to 

be taken. The conrtittee shall give its opinion within a period set by the 

chairman  according  to the urgency of the matter, decided by a vote if 

necessary. 

2.  The  opinion  shall be  recorded  in the  report of the meeting; moreover, 

each Member State shall have the right to have its own opinion recorded 

in the report. 

3.  The Commission shall take due note of the opinion given by the committee. 

It  shall  inform  the  committee  of  the procedures  through  which  that 

opinion was taken into consideration. 

Article 7 

The procedures laid down in Article 6 shall apply in particular to: 

the contents of the calls for proposals; 

the assessment of the proposed projects and the estimated amount of the 

Community's contribution to themj 

departures from the general rules governing Community participation set 

out in the Annex;, 

the  participation 

in  any  project  by  non-Coramunity organizations and 

enterprises referred to in Article 8(2); 

the measures to be undertaken to evaluate the programme; 

arrangements  for the dissemination, protection and exploitation of the 

results of research carried out under the programme. 

Article S 

1.  The  Commission  is  authorized,  in  conformity  with  Article  130  N of  the  EEC 
Treaty,  to  negotiate  agreements  with  non-member  States  and  international 
in 
o r g a n i z a t i o n s,  p a r t i c u l a r ly  with  non-member  S t a t es  taking  part 

- 10 -

European cooperation  in the field of scientific  and technical research 

(COST) and with countries which have concluded scientific and technical 

framework  cooperation  agreements  with  the Community,  with  a  view  to 

associating them fully or partially with the programme. 

2.  VThere  framework  agreements  for  scientific  and  technical  co-operation 

between European non-Member States and the European Communities have been 

concluded, organizations  and enterprises established in those countries 

may, on the basis of the criterion of mutual benefit, become partners in 

a project undertaken within the programme. 

Article 9 

This Decision is addressed to the Member States. 

Done at 

, 

.....1989 

For the Council, 

The President 

- 11 -

ANNEX 

for a specific research programme in the field of health: 

Human Genome Analysis 

1.  OBJECTIVES 

Use and improvement of new biotechnologies in the study of the human genome 

for a better understanding of the mechanisms of genetic function, as well as 

the  prevention  and  treatment  of  human  diseases. In  the  pursuit  of  these 

objectives, optimal cooperation will be sought with the programmes of non-

member States and international organizations. 

At the same time measures will be taken to develop an integrated approach to 

the ethical, social and  legal  aspects of possible  applications of results 

obtained through the programme to ensure that they are not misused and also, 

with  prenormative  aspects  in  mind,  to  establish  a  set  of  bioethical 

principles to be followed in the developments to come. 

Alteration of germ cells or any stage of embryo development with the aim of 

modifying human genetic characteristics  in a hereditary manner  is excluded 

from the programme objectives. 

2.  TECHNICAL CONTENT 

Precompetitive Ccmnunity research, setting up and reinforcement of networks 

of European laboratories, and training, intended to allow the use of modern 

technologies for the study and setting up of the human genetic map as well as 

possible medical applications of the knowledge gained. 

The  research  described  below  will  require  the  use  of  data-processing 

facilities  for  the handling  of  data, and  the development  of  integrated 

databases to serve European networks. 

2.1 IMPROVEMENT OF THE HUMAN GENETIC MAP 

- 12 -

Establishment  of  a  Europe-based  network,  extending  worldwide,  for  the 

collection  and mapping  of the DNA of  large families, in order  to provide 

research  scientists with well-characterized genetic  material  and  sets  of 

probes to determine the location of the relative positions of genes on the 

chromosomes. 

2.2 SETTING UP OF ORDERED CLONE LIBRARIES OF HUMAN DNA 

Setting  up  of  a  European  network  of  laboratories  working  on  establishing 

overlapping clone libraries, and support for limited sequencing of cDNA. 

2.3 IMPROVEMENT OF THE METHODS AND BASIS FOR THE STUDY OF THE HUMAN GENOME 

New biochemical reagents (restriction enzymes, etc.). Improvement of methods 

for  the  detection  and  localization  of  genetic  markers  (techniques  for 

labelling  DNA probes, amplification  of  genes, etc.).  Development  of  new 

vectors  for  the cloning  of  large DNA  fragments  and of procedures  for the 

transfection  of  chromosomes.  Development  of  model  systems  for  the 

reproducible and stable expression of medically important genes both in vivo 

and  in  vitro  aimed  at  the  well-being  of  patients. Development  of  new 

computer  software  for  the  storage  and manipulation  of  data  from  genome 

sequencing and mapping. 

2.4 TRAINING 

Setting up of a training programme to assist with the technology transfer of 

molecular  genetics methods, in particular  to Member States  in which  these 

techniques are currently underdeveloped. 

3.  BPU34ENTATION 

3.1 The programme  shall be implemented through cost-shared or marginal cost 

contracts,  support  to  centralized  facilities  and  networks,  training 

contracts, training grants, courses, consultations with national experts, 

organization  of  study-group meetings, participation  in  seminars  and 

symposia,  publications,  studies,  dissemination  of  results  to  all 

interested groups, and organization of public presentations. 

- 13 -

Community  participation will be up  to a maximum of 50% in the case of 

cost-shared contracts and could reach 100% in other cases. 

Participants  may  be  research  institutions,  universities,  private 

enterprises, or combinations of them, located in Member States or in the 

non-member States referred to in Article 7, or competent organizations in 

a position to make a significant contribution. 

Projects must be carried out by participants from more than one country, 

and include at least one participant from one Member State. 

Fellows coming  from non-^nember States will be accepted in the training 

programme, provided that they meet the required conditions and that their 

costs are covered from other sources, such as other Community programmes 

or actions which support fellows coming from developing countries. 

The contracts concluded by the Commission will govern the rights and the 

obligations  of  each  party,  in  particular  the  means  of  distribution, 

protection and exploitation of the results of the research. 

3.2 The  drawing  up  of  research  contracts  can  only  take  place  if  the 

contracting  parties  undertake  to abstain  from  all  research  seeking  to 

modify the  genetic  constitution  of human  beings by  alteration  of germ 

cells  or  of  any  stage  of  embryo  development  which  may  make  these 

alterations hereditary. 

The  contracts  shall  regulate  the  granting  of  licences  arising  out  of 

research projects and in particular there shall be no right to exploit on 

an  exclusive  basis  any property  rights  in  respect  of  human  DNA.  In 

addition, the Commission shall reserve the right to publish the results 

of the research performed within the scope of the contracts. 

The  contracts  will  guarantee  that  the  members  of  the  families 

participating  in the studies referred to in paragraph 2.1 above will be 

fully informed about and have consented to the use and study of their 

DNA.  The  contracts  will  also  guarantee  complete protection  of  the 

confidentiality  and anonymity  of  the personal  data, obtained  in  the 

programme. 

- 14 -

3.3 The Commission  will  ensure  that  during  the  execution  of the  programme 

there will  be wide-ranging  and  in-depth  discussions  of  the  ethical, 

social  and  legal  aspects  of  human  genome  analysis  and  that  possible 

misuses will be identified regarding applications of the results obtained 

or of future developments of that research. It will ensure that the far-

reaching consequences of the research will be evaluated in a responsible 

manner, and will submit to the Council and to the European Parliament an 

annual report, possibly with legislative recommendations arising as much 

from the research policy angle as frcm the legal one. To this end, the 

Commission  will  obtain  advice  from  experts  in  different  fields  of 

science,  law,  philosophy  and  ethics, together  with  representatives  of 
patients1 associations. 

4.  EVALUATION CRITERIA 

The  Communication  from  the  Commission  to  the  Council  relating  to  the 

evaluation  of Community  research  and  development programmes(°) states that 

the objectives and milestones for each research programme have to be set out 

in verifiable and, where possible, quantitative form. These reference marks 

are listed below: 

4.1 The  long-term objective of this programme  is to contribute to a better 

understanding  of the mechanisms of  genetic  function  as well  as  to the 

fight  against  human  diseases  arising  from  genetic variation  (including 

genetic  diseases  sensu stricto and many common  diseases with  a genetic 

component,  such  as  heart disease and cancer), through early diagnosis, 

prevention,  and  improvement  of  prognosis  and  therapy.  The  Commission 

proposes to achieve this objective by: 

- the  management  of  networks  of  laboratories  set  up  around  European 

facilities for (a) the improvement of the human genetic map and (b) the 

setting  up  of  ordered  clone  libraries  of  human  DNA,  either  of  the 

complete  genome  or  of  selected  chromosomes,  together  with  cDNA 

sequencing; 

6) OJ N° C 14, 20.1.87, p. 5 

- 15 -

- the  launching  of  a  programme  of  precompetitive  research  aiming  at 

improvement of the methods and basis for the study of the human genome; 

- the setting up of a programme of training to increase the distribution 

of modern genetic technologies in Europe, and to improve technological 

know-how in European laboratories; 

- the promotion  of cooperation with non-member States and international 

organizations. 

4.2 The primary short-term objective is that the programme should succeed in 

establishing the above-mentioned European networks of laboratories in the 

fields of: 

- the human genetic map 

- ordered clone libraries of human DNA and cDNA sequencing 

- improvement of the methods and basis for the study of the human genome, 

all  using  data-processing  facilities  for  data-handling  and  developing 

integrated data bases. 

These objectives should be verifiable in 1991. 

4.3 Particular objectives to be attained within two years of the programme 

implementation are as follows: 

4.3.1 Concerning the human genetic map: 

- the present total of 40 well-studied  large families which form the 

basis for the genetic map should be increased to 60 families; 

- genetic material frem these families, and DNA probes, should be made 

available to the European laboratories concerned while respecting the 

individual rights of those families; 

- a  central  facility  should be  identified  to pool  the  results  and 

establish  an  improved genetic map at the 1 to 5" centimorgan level, 

and  an integrated databank should be set up. 

- 16 -

4.3.2 The  strategies  for  setting  up  ordered  clone  libraries  of  human  DNA 

should be  compared  and  a  better  approach  defined;  facilities  for 

maintaining  the stocks of cloned DNA fragments should be established, 

and  the  available  clones  dispatched  to  interested  European 

labofa" tories. 

4.3.3 Substantial  improvements  should be obtained in the following research 

fields to improve the methods and the basis for the study of the human 

genome: 

- New reagents, such as restriction enzymes, 

- Methodology for cloning large DNA fragments and for the transfection of 

chromosomes, 

- Gene vectors adapted to human somatic cells in vitro, 

- Ifethodology for the detection of a particular gene in a cell, 

- Localization, cloning  and  sequencing  of  new  genps, especially  those 

which are disease-related, 

- New computer software for the storage, collation and analysis of DNA 

sequence data. 

4.4 In  addition,  the  programme  should  ensure  that  the  following  general 

criteria are met: 

4.4.1 That throughout the execution of the programme, the ethical, social and 

legal aspects of human genome analysis should be the subject of wide-

ranging and in-depth discussions, and possible abuses of the results or 

later developments  of  the work  should  be  identified; principles  for 

their utilization and control should be proposed. 

4.4.2 That  the drawing  up  of  research  contracts  shall presuppose  that the 

contracting parties undertake to abstain from all research  seeking to 

nodify the genetic constitution of human beings by alteration of germ 

cells  or  of  any  stage  of  embryo  development  which  may  make  these 

alterations hereditary. 

- 17 -

4.4.3 The members  of  the  families  taking  part  in the studies mentioned in 

paragraph 2.1 must have been informed and given their consent, and the 

confidentiality and anonymity of personal data must be ensured. 

4.4.4 That  the development  and the application of somatic gene therapy are 

not provided for within the framework of the present programme. 

4.4.5 That actual or potential medical applications should be facilitated. 

4.4.6 That  potential  opportunities  for  commercial  developments  should  be 

obtained. 

4.4.7 That the overall technological  standard of the participating European 

laboratories must have been improved. 

4.4.8 That taking account of the results of Community, national or commercial 

research  activities  in  human  genetics, the  evaluation  panel  should 

consider  whether  the  human  genome  analysis  has  contributed  to  the 

development of the results of  the  said  activities  in regions  of  the 

Community other  than those  in which  the research was conducted. The 

evaluation panel should also ascertain whether  cooperation with non-

member States and international organizations has indeed been achieved 

and whether this cooperation has had positive results. 

• 

-AS-

FICHE FINANCIERE 
PROGRAMME  ANALYSE PU CENOME HUMAIN 

Les  points  1  à  4  de  la fiche financière originale de la proposition 
COH<88)424 restent  inchangés. 

5. 

INCIDENCE FINANCIERE PE L'ACTION SUR LES CREP1TS D'INTERVENTION 

(Y conprls les dépenses de personnel  (l  agent  de  catégorie  A, 1 
agent 
les  dépenses  de  fonctionnement 
administratif et technique). 

catégorie 

C)  et 

de 

5.1. Çoftt tOtll M m U lU  tPUtt 11 dUTéi «lYllMto 
5.2. Part dans la financement 
• du budget communautaire 
- des budgets nationaux et  ) 
- d'autres secteurs au 

niveau national 

) . . . . .. 
) 

5.3. Echéancier plurlannuel du budget cosmunautalre 

5.3.1. Crédits d'engagement  en Millions d'Ecua 

Personnel 
Fonctionnement 
Contrats et bourses 

looo» 

0,21 
0,20 
12,09 

îooi 

0.21 
0,25 
2,04 

Total 

12,5 

2,5 

^  »i° Ecus 

15 Mio Ecus 

15 Mio Ecus 

TSiïâL 

0,42 
0,45 
14,13 

15,00 

5.3.2. Crédita de paiement en Million* d'Ecua 

1000» 

1001 

1002 

1993 

I P J AL 

Personnel 
Fonctionnement 
Contrats et bourses 

0,21 
0,20 
3,79 

0,21 
0,25 
5,54 

• 
-
3,10 

* 
-
1,70 

0,42 
0,43 
14,13 

Total 

4,2 

6,0 

3,10 

1,70 

15,00 

* Ces montants  figurent à 1*APB 90 - Ht  sont aujeti à modification 

au cours de la procédure budgétgalre en cours. 

ISSN 0254-1475 

COM(89) 532 final 

DOCUMENTS 

EN 

05 

Catalogue number : CB-CO-89-485-EN-C 

ISBN 92-77-54138-5 

Office for Official Publications of the European Communities 
L-2985 Luxembourg